NR 3-4/2003
|
|
|
|
|
|
|
|
|
Leczenie krwotoków podsiatkówkowych w plamce
doszklistkowym podawaniem tkankowego aktywatora plazminogenu oraz gazu SF6
Management of subretinal macular haemorrhages with
intravitreous injections of tissue plasminogen activator and SF6 gas
Jolanta Oficjalska-Młyńczak, Hanna Zając-Pytrus, Jarosław
Marek, Maria Hanna Niżankowska
Z Katedry i Kliniki Okulistyki Akademii Medycznej we Wrocławiu
Kierownik: prof. dr hab. n. med. Maria Hanna Niżankowska |
|
|
| Summary: |
Purpose: of our retrospective study was the
estimation of the efficacy of recombinant tissue plasminogen activator (tPA) and
intravitreal injections of SF6 gas in cases of subretinal macular haemorrhages.
Material and methods: In 20 patients aged 23-83 years, the subretinal
macular haemorrhages were diagnosed, due to senile macular degeneration (9), hypertension
(3), myopic retinochoroidal degeneration (3), other retinal heredodegeneration (2),
retinal macroaneurysm (2) and trauma (1). We injected the solution of recombinant tissue
plasminogen activator - Actilise (Boehringer Ingelheim) into vitreous cavity of these
eyes. After lowering IOP, the intravitreous injections of 0,5 ccm SF6 gas were done, and
following 24 hours down head positioning were carried out.
Results: The initial visual acuity before treatment was: HM or CF, from
less then 1 meter in most of our cases (12 patients). The after treatment visual acuity
ranged CF from 2 meters to 0,7. The early treatment conditioned better acuity. Even in
cases of delayed treatment, the diminishing of central visual scotoma could be awaited.
Conclusions: The new method of treatment in cases with subretinal macular
haemorrhages despite of its symptomatic characters seems to be helpfull in restoring the
central vision in some cases. |
| Słowa kluczowe: |
krwotok podsiatkówkowy w plamce, fibrynoliza, tkankowy
aktywator plazminogenu, SF6 gaz. |
| Key words: |
subretinal macular haemorrhage, fibrinolysis, tissue
plasminogen activator (tPA), SF6 gas. |
|
|
|
|
|
|
